Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel and high efficiency anti-addiction drug

A drug and addiction technology, applied in the field of new high-efficiency anti-addiction drugs, can solve problems such as side effects, large individual differences of thienorphine, and limited clinical application

Active Publication Date: 2018-09-14
TEIZHOU HUAYUAN MEDICINAL TECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, thienorphine varies greatly among individuals and has obvious side effects, which limits its clinical application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel and high efficiency anti-addiction drug
  • Novel and high efficiency anti-addiction drug
  • Novel and high efficiency anti-addiction drug

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0028] 1.7 Thienomorphine (C 1 ) preparation

[0029] 1.2g (2mmol) vii 1 Dissolve in 5ml of anhydrous tetrahydrofuran, add 2ml of 2M LiAlH dropwise under stirring 4 Tetrahydrofuran solution; after adding, stir overnight at room temperature; then add magnesium sulfate heptahydrate in batches until no gas is released. Filtrate, evaporate the filtrate to dryness under reduced pressure, separate by silica gel column chromatography, elute with petroleum ether: dichloromethane: methanol = 4: 1: 0.1, collect the required components, and recrystallize with methanol to obtain C 1 0.75g; Dissolve this solid with ethanol, add hydrogen chloride ether solution, to pH2, stir, precipitate solid, after standing overnight, filter and wash with anhydrous ether to obtain C 1 ·HCl 0.61g, melting point: >200°C. 1 H-NMR (400MHz, DMSO-d6): 9.62 (br, 1H); 9.39 (br, 1H); 7.26 (m, 1H); 7.01 (d, 1H); 6.91 (m, 1H); 1H); 6.55(d, 1H); 4.64(br, 1H); 4.54(s, 1H); 3.90(d, 1H); 3.41(s, 3H); 3.28(m, 2H); 3...

Embodiment 1

[0036] Example 1 (2S)-2-[(5R, 6R, 7R, 14S)-N-(cyclopropyl-dideuteriomethyl)-4,5-epoxy-6,14-ethylene- 3-Hydroxy-6-methoxymorphinan-7-yl]-4-(thiophen-2-yl)-butan-2-ol (I 1 ) preparation

[0037]

[0038] With reference to the method of reference example 1.7, vii 1 with LiAlD 4 (% D: > 98) reaction, makes I 1 ; will I 1 Dissolve in ethanol, form a salt with hydrogen chloride, and obtain I 1 · HCl, melting point: >200°C. 1 H-NMR (400MHz, DMSO-d6): 9.60 (br, 1H); 9.34 (br, 1H); 7.26 (m, 1H); 7.00-6.90 (m, 2H); 6.73 (d, 1H); d, 1H); 4.64(br, 1H); 4.54(s, 1H); 3.90(d, 1H); 3.30-2.30(m, 7H); 2.28(m, 1H); 1.96(m, 2H); 1.82 (m, 2H); 1.70(m, 1H); 1.51(m, 1H); 1.47(m, 1H); 1.35(m, 1H); 1.30(s, 3H); 1.13(m, 1H); 0.67( m, 2H); 0.58(m, 2H); 0.39(m, 1H).

Embodiment 2

[0039] Example 2 (2S)-2-[(5R, 6R, 7R, 14S)-N-(cyclopropyl-dideuteromethyl) 4,5-epoxy-6,14-ethylene-3 Preparation of -Hydroxy-6-methoxymorphinan-7-yl]-4-(thiophen-3-yl)-butan-2-ol ()

[0040]

[0041] With reference to the method of reference example 1.7, vii 2 with LiAlD 4 (% D: > 98) reaction, makes I 2 ; will I 2 Dissolve in ethanol, form a salt with hydrogen chloride, and obtain I 2 HCl, H NMR spectrum: 1 H-NMR (400MHz, DMSO-d6): 9.66 (br, 1H); 9.37 (br, 1H); 7.43-7.02 (m, 3H); 6.73 (d, 1H); 6.55 (d, 1H); 4.64 ( br, 1H); 4.54(s, 1H); 3.90(d, 1H); 3.28-2.79(m, 7H); 2.26(m, 1H); 1.95-1.70(m, 5H); 2H); 1.37(m, 1H); 1.32(s, 3H); 1.12(m, 1H); 0.36(m, 1H); 0.59(m, 2H); 0.68(m, 2H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound of structural formula (I) and a non-toxicity pharmaceutically acceptable salt thereof, wherein R represents H or an alkyl group with 1 to 3 carbon atoms; the purpose of any compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is to prepare a drug for treating an addiction disease; and the addiction disease is selected from cocaine addiction, methylamphetamine type drug addiction, opium type drug or medicine addiction, alcoholic addiction, smoking addiction or ketamine addiction.

Description

technical field [0001] The present invention relates to novel deuterated N-cyclopropylmethyl-noripavine derivatives or pharmaceutically acceptable salts thereof with anti-addiction effects, pharmaceutical compositions containing these compounds as active ingredients, and the Derivatives or pharmaceutically acceptable salts thereof are used in the preparation of drugs for detoxification. Background technique [0002] Drug abuse and addiction seriously threaten human physical and mental health. Thienorphine has a strong antagonism to morphine, and is being used in clinical research for the treatment of opioid addiction. However, thienorphine varies greatly among individuals and has obvious side effects, which limit its clinical application. [0003] [0004] The object of the present invention is to provide thienorphine analogues that are orally effective and have better morphine antagonism. Contents of the invention [0005] The present invention provides compounds re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D489/12A61K31/485A61P25/30A61P25/32A61P25/34
CPCC07D489/12
Inventor 仲伯华付仁芳杨家俊
Owner TEIZHOU HUAYUAN MEDICINAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com